CFR

Alzheimer’s Drug Discovery Foundation and Harrington Discovery Institute Center for Brain Health Medicines Invite Proposals for 2024 ADDF-Harrington Scholar Award. The ADDF-Harrington Scholar Award is designed to accelerate the translation of innovative research that could treat, prevent, slow, or reverse Alzheimer’s disease or related dementias.

This call is open to academic investigators at accredited medical centers, research institutions, and universities in the United States, Canada, and the United Kingdom. Researchers working on drug development programs that are relevant to, but not presently focused on, the Alzheimer’s field are strongly encouraged to apply.

This award provides a combination of financial support and expert drug development guidance. Award recipients will receive financial support up to $600,000 over two years, dedicated drug development and project management support, and an opportunity to qualify for investment funds.

The 2024 ADDF-Harrington Scholar RFP places high priority on targets related to emerging therapeutic areas for dementia, particularly:
Proteostasis (including autophagy, lysosomal biogenesis, proteasomal degradation, post-translational modification associated with proteostasis, protein folding/misfolding, ER stress, extracellular clearance)
Senescence (including cells that have halted division, shifted towards a secretory phenotype, altered morphology and epigenetics, and decreased apoptosis)

Other novel targets are encouraged. These include, but are not limited to, the following:
Epigenetics
Vascular pathology
Neuroprotection
Synaptic activity and neurotransmitters
Inflammation
Mitochondrial health
Antioxidant defense
Metabolic function and brain energy
Brain insulin resistance
APOE
Glymphatic clearance
Postnatal neurogenesis
Other aging targets

Letters of Intent (LOI) must be submitted online here and will be accepted through June 3, 2024 at 5:00 pm EDT.

Learn More